RCS - GENinCode PLC - ShareSoc investor presentation

GenincodeAnnouncement

12/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231012:nRSL8485Pa&default-theme=true

RNS Number : 8485P  GENinCode PLC  12 October 2023

GENinCode Plc

("GENinCode" or the "Company")

 

ShareSoc investor presentation

Presentation at ShareSoc & Walbrook PR Healthcare Companies Hybrid Event

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused
on the prevention of cardiovascular disease, announces that Matthew Walls, CEO
will provide a live presentation to investors at the ShareSoc & Walbrook
PR Healthcare Companies Hybrid Event on Thursday 19 October 2023.

 

The event will start at 5pm, with registration at 4.30pm and will take place
in London at ISH Venues, 1 Park Crecent, W1B 1SH. All attendees, both
in-person and virtual, will have the opportunity to ask questions and those
attending the seminar will be able to network with company directors and
fellow investors over drinks and a buffet. No new material information will be
disclosed in the presentation.

 

To register for the event and for further details, please click on the
following link
(https://www.sharesoc.org/sharesoc-walbrook-pr-healthcare-companies-hybrid-event-london-19-october-2023-5pm/)
.

 

For more information visit www.genincode.com (http://www.genincode.com)

 

Enquiries:

 

 GENinCode Plc                            www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO
 Paul Foulger, CFO

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                                        Tel: +44 (0)20 7710 7600
 Alex Price / Ben Maddison / Richard Short

 Cavendish Securities Plc (Joint Broker)  Tel: +44 (0)20 7397 8900
 Giles Balleny
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited

 Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage                   Tel: 020 7933 8780 or genincode@walbrookpr.com
                                                                      (mailto:genincode@walbrookpr.com)

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict the
onset of cardiovascular disease.

 

About Cardiovascular Disease (CVD):

 

CVD is the leading cause of death globally, taking an estimated 17.9 million
lives each year. CVD is a group of disorders of the heart and blood vessels
and include coronary heart disease, cerebrovascular disease, rheumatic heart
disease and other conditions. More than four out of five CVD deaths are due to
heart attacks and strokes, and one third of these deaths occur prematurely in
people under 70 years of age.

 

CVD causes a quarter of all deaths in the UK and is the largest cause of
premature mortality in deprived areas with the NHS 10 Year Plan identifying
CVD as the single biggest area where the NHS can save lives over the next 10
years. CVD is largely preventable, through lifestyle changes and a combination
of public health and NHS action on smoking and tobacco addiction, obesity,
tackling alcohol misuse and food reformulation.

 

Early detection and treatment of CVD can help patients live longer, healthier
lives. Too many people are still living with undetected, high-risk conditions
such as high blood pressure, raised cholesterol, and atrial fibrillation (AF).
The NHS 10 Year Plan is working towards people knowing and managing risks
around their 'ABC' (AF, Blood pressure and Cholesterol).

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFLFWFEDSEIS